Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GHSR | Q92847 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13908402 | 0.85 | POLB (0.49) | LMNAMAPK1POLBKMT2AGAA | |
| SCHEMBL4172989 | 0.81 | PDE4A (0.64) | MAPK1POLBALDH1A1GAATSHR | |
| SCHEMBL4194160 | 0.81 | PDE4A (0.64) | MAPK1POLBALDH1A1GAATSHR | |
| SCHEMBL4180198 | 0.81 | PDE4A (0.64) | MAPK1POLBALDH1A1GAATSHR | |
| SCHEMBL4191674 | 0.76 | ALOX15 (0.53) | LMNAMAPK1POLBKMT2AALDH1A1 | |
| SCHEMBL4172976 | 0.75 | PDE4A (0.69) | MAPK1POLBKMT2AALDH1A1GAA | |
| SCHEMBL4180103 | 0.74 | PDE4A (0.71) | MAPK1POLBKMT2AALDH1A1GAA | |
| SCHEMBL1382478 | 0.72 | ALDH1A1 (0.53) | LMNAMAPK1POLBKMT2AALDH1A1 | |
| SCHEMBL4181513 | 0.72 | ALDH1A1 (0.86) | LMNAMAPK1POLBKMT2AALDH1A1 | |
| SCHEMBL3806662 | 0.72 | ALDH1A1 (0.62) | LMNAMAPK1KMT2AHTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | claimed |
| EP-1976498-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-10-08 | — | — | EP | claimed |
| WO-2007127505-A2 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | WO | claimed |
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| EP-1976498-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007127505-A2 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127505-A2 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069302-A1 | CHEMICAL COMPOUNDS | TBXA2R, PDE4D, PDE4A | LMNA 3674/4885MAPK1 1720/4885POLB 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.